Conference Day One
8:30 am Check-In & Coffee
8:50 am Chair’s Opening Remarks
Discussing The Progress in The Field & Addressing Common Challenges Within Tissue Modelling
9:00 am Panel: Navigating the 3D Tissue Modelling Landscape Focusing on Model Adoption & Current Regulatory Frameworks
Synopsis
- Discussing the need for common benchmarks and standards to ensure comparability and reproducibility across different laboratories and research settings
- Sharing insights and experiences from industry leaders on best practices, to bring these technologies internally by making a business case
- Addressing the current regulatory landscape for accepting data from 3D tissue models in drug development
9:45 am Establishing Translational Centers for MPS Towards Regulatory Qualification as Drug Development Tools
Synopsis
- NCATS/NIH will discuss its newest programs that will facilitate regulatory acceptance of MPS
- NCATS/NIH will discuss hurdles to overcome in the MPS/CIVM field, and the future of the program
- NCATS/NIH will discuss the newest NIH Common Fund’s Complement Animal Research in Experimentation (Complement-ARIE) program, which will speed the development, standardization, validation, and use of human-based new approach methodologies
10:15 am Morning Break & Speed Networking
Synopsis
As the 3D tissue modelling community is reunited, this valuable session will ensure you get the chance to reconnect with peers and make brand new connections! This structured networking opportunity will pair you with fellow attendees for several 3-minute introductions, ensuring you have the opportunity to meet and network with your academic and industry colleagues!
11:15 am Tackling Cancer Pathophysiology Through Microphysiological Systems
Synopsis
- Examining the capabilities and advantages offered by MPS in providing unprecedented insights into cancer biology and drug responses
- Assessing best practices and strategies for maintaining replicability, contributing to the reliability of data generated in the process of cancer drug discovery
- Exploring strategies to ensure the scalability of these systems, laying the groundwork for their future impact in advancing cancer research and therapeutics
11:45 am Session Reserved for MIMETAS
12:15 pm Enhancing Therapeutic Insights from a Tumor Fragment Model
Synopsis
- Highlight the utility of cryo-preserved tumor fragments in designing studies that involve treating fragments with different combination regimes
- Discuss the flexibility of this model, allowing for varied drug treatments and the subsequent collection of supernatant for in-depth analysis
- Discuss the potential insights gained from these analyses, contributing to a deeper understanding of tumor biology and therapeutic responses
12:45 pm MiNK-215, an IL-15 Armored FAP-Targeting CAR iNKT Cell Therapy, Effectively Treats Human Organoid Models of Treatment-Refractory MSS Colorectal Cancer (CRC) Liver Metastases
Synopsis
- Exploring methods for validating liver organoid models to ensure accurate representation of the liver metastases tumor microenvironment
- Optimizing Organoid – immune cell co-culture for use in immune-oncology
- Screening combination therapies
1:15 pm Lunch Break
Leveraging Organoids to Organ-On-A-Chip Technology to Gain Better Disease Insights
2:15 pm Recapitulating The Lung Pathobiology Using Organoids & Organ-On-A-Chip
Synopsis
- Sharing methodologies to validate biology of these models to assess for idiopathic fibrosis
- Implementing spatial biology techniques to validate model components and break-down biology into mechanism-based assays to enable screening
- Discussing the multidimensional insights provided by these models together with validated human clinical biomarkers for a thorough understanding of the expected drug effects on the health of the patient
2:45 pm Implementing 3D Culture Platforms for Target Validation in Kidney Diseases
Synopsis
- Uncovering how renal 3D-ex-vivo cell culture provides a physiologically relevant platform for precise studies, offering deeper insights into renal pathophysiology
- Highlighting techniques to culture ex-vivo isolated glomeruli that are better representative of kidney morphology
- Exploring the data from these 3D models using high-content focal imaging, and proteomics to support target validation
3:15 pm Scientific Poster Session & Refreshments Break
Synopsis
Witness some of the latest and greatest research in the 3D tissue modelling field by drug
developers, academics, and researchers in this spotlight poster session.
Uncovering Best Practices to Ensure Consistency & Replicability Across Different Models
3:45 pm Mastermind Session: Best Practices for Sample Sourcing & Scaling Up Your Workflow
Synopsis
- Uncover with your peers their best practices in selecting the right collaborator to provide patient samples and ensuring sample quality is maintained to support your study
- Share your lessons learned and strategies to scale up your model in your work
- Discuss innovative ideas and next steps that you can use to improve your current workflows
4:15 pm Establishing Consistency and Increasing Throughput: Applications to Improve 3D Cell Culture Workflows
Synopsis
- Maximizing experimental results through utilization of existing products
- How to integrate multiple tools to generate more data per experiment
- New tools to improve scalability of 3D workflows
4:45 pm Developing Organoids to Better Understand the Intestinal System
Synopsis
- Exploring the advancements in developing intestinal organoids as a robust platform for screening therapeutics
- Discussing how insights gained from the study of intestinal organoids contribute to optimizing regenerative approaches, offering new avenues for therapeutic development
- Uncovering best practices for maintaining replicability and explore considerations for scaling up these models to meet the demands of future drug discovery endeavors